Enteral oxygen therapy
PreclinicalSmall molecule
Enteral oxygen therapy is one of 9 small molecule programs targeting Rehabilitation. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Gastritis
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mononuclear Cells
NNational University of Malaysia
Preclinical
Talcid
BayerPreclinical
Enteral oxygen therapy
TTashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastritis1 trial
To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology (CGDP) in Schoolchildren in the Primary Health Care System.
Active, not recruiting·TTashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan·Preclinical·NCT04702542·320 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enteral oxygen therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details